ZIOPHARM Oncology Inc (ZIOP) financial statements (2021 and earlier)

Company profile

Business Address ONE FIRST AVENUE
BOSTON, MA 02129
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1158062718114143
Cash and cash equivalents1158062718114143
Receivables5320000
Other undisclosed current assets1122212024111
Total current assets:131105849110515344
Noncurrent Assets
Operating lease, right-of-use asset52
Property, plant and equipment10111111
Deposits noncurrent assets0000000
Other noncurrent assets101013000
Total noncurrent assets:1641115111
TOTAL ASSETS:1461099510610615445
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities181291491111
Accounts payable1114022
Accrued liabilities1711910997
Employee-related liabilities      1
Debt11     
Deferred rent credit  0
Deferred revenue and credits7772
Other undisclosed current liabilities      (1)
Total current liabilities:1813921161811
Noncurrent Liabilities
Long-term debt and lease obligation42     
Finance lease, liability42
Liabilities, other than long-term debt  03843481
Deferred revenue and credits3542481
Deferred rent credit  0
Derivative instruments and hedges, liabilities   21  
Total noncurrent liabilities:4203843481
Total liabilities:2214958586611
Stockholders' equity
Stockholders' equity attributable to parent1249586(97)(77)8734
Common stock0000000
Additional paid in capital888779652615581580406
Accumulated deficit(764)(684)(566)(712)(658)(493)(373)
Other undisclosed stockholders' equity   144125  
Total stockholders' equity:124958647488734
TOTAL LIABILITIES AND EQUITY:1461099510610615445

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net6741
Gross profit:  06741
Operating expenses(80)(58)(54)(60)(172)(124)(57)
Other undisclosed operating income      12
Operating loss:(80)(58)(54)(53)(165)(120)(43)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
011000(0)
Net loss:(80)(57)(53)(53)(165)(120)(44)
Other undisclosed net income (loss) attributable to parent (61)0(1)(0) 12
Net loss attributable to parent:(80)(118)(53)(54)(165)(120)(32)
Preferred stock dividends and other adjustments  190(19)(7)  
Net income (loss) available to common stockholders, basic:(80)(118)137(73)(172)(120)(32)
Dilutive securities, effect on basic earnings per share  201    
Net income (loss) available to common stockholders, diluted:(80)(118)339(73)(172)(120)(32)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(80)(57)(53)(53)(165)(120)(44)
Comprehensive loss, net of tax, attributable to parent:(80)(57)(53)(53)(165)(120)(44)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: